One of the principal advantages of the use of mobilized blood progenitor cells (BPC) over bone marrow for autologous transplantation is the more rapid blood cell recovery observed after BPC transplants. Both neutrophil and platelet recoveries have been reported to occur, on average, 1 week earlier with resulting decreases in transfusion requirements, antibiotic utilization and hospitalization. [1] [2] [3] For clinical purposes, BPC mobilization is accomplished with the use of myelosuppressive chemotherapy and/or hematopoietic growth factors. 1, [4] [5] [6] [7] [8] It is known that the numbers of CD34
+ cells or granulocyte-macrophage progenitors mobilized can be enhanced by administering combinations of different cytokines, [9] [10] [11] [12] by combining the use of cytokines with prior cytotoxic drugs 4, 13, 14 or by increasing the dose of a single cytokine. 15 However, it is not clear whether such maneuvers can differentially affect the mobilization of specific types of progenitors or the pattern of neutrophil or platelet recovery post transplant, particularly in patients with extensive prior therapy. [16] [17] [18] Since the introduction of growth factors such as granulocyte colony-stimulating factor (G-CSF) for clinical use, BPC mobilization has been relatively easy to accomplish and neutrophil recovery after transplantation of G-CSF mobilized BPC has been generally reliable. 1 However, in most series of autologous BPC transplants, a significant proportion of patients demonstrate delayed platelet recovery. 1, 7, 8 This is particularly true among patients who have had extensive chemo/radiotherapy prior to BPC harvest. Thus, factors that would allow such patients to be identified beforehand are of clinical importance and potentially useful for developing strategies to overcome this problem. In this study, we measured the number of megakaryocyte colonyforming cells (CFC-Mk) 19 and cells that generate erythroid and granulopoietic progenitors after 10 to 56 days in longterm culture (LTC) 20 in mobilized BPC collections from 90 cancer patients. These values, as well as the quantities of CFC measured directly in standard methylcellulose assays and CD34 + cells measured by flow cytometry, 21 were used to compare the progenitor mobilizing effect of four different treatment regimens and to establish threshold values of these populations which predict platelet recovery in recipients of autologous BPC transplants.
Materials and methods

Patients
Ninety patients with advanced malignancy (median age 40.5 years) were referred to the Cell Separator Unit at the Vancouver General Hospital for the collection of BPC for autologous transplantation between January 1991 and February 1997 (Table 1 ). Marrow cells for LTC feeder layers (see below) were obtained from normal donors of allogeneic transplants or cadaveric marrow specimens (Northwest Tissue Center, Seattle, WA, USA). These studies were done with informed consent and the approval of the Clinical Screening Committee for Research Involving Human Subjects of the University of British Columbia (Vancouver, BC, Canada).
All of the patients had received previous chemotherapy and/or radiotherapy for their primary malignancy. Previous studies in mice 17 have demonstrated the ability of alkylating agents in particular to reduce the self renewal potential of primitive stem cells. In man, prior exposure to these agents has been associated with poor mobilization of BPC. 16, 18, 22, 23 The same adverse effect on BPC collections has been associated with previous radiotherapy. Among the patients in this study 44 were considered to have received prior chemotherapy or radiotherapy extensive enough to potentially compromise BPC mobilization. These include 24 patients who had received at least three cycles of drugs known to be among the most potent 'stem cell toxins' (ie melphalan, nitrogen mustard or nitrosoureas 16 ) or at least six cycles containing other alkylating agents such as procarbazine and cyclophosphamide. 23 The remaining 20 patients had received radiation to the mediastinum, abdomen or pelvis in addition to various chemotherapy regimens 18 (n = 20).
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BPC collection
Forty-seven patients were given cyclophosphamide (Cy) at a dose of 7 g/m 2 followed immediately by daily s.c. injections of either IL-3 (Novartis, Basel, Switzerland) 5 g/kg/day with GM-CSF (Novartis) 5 g/kg/day (n = 10), or GM-CSF 5 g/kg/day only (n = 7) or G-CSF (Amgen, Thousand Oaks, CA, USA) 12 g/kg/day only (n = 30) until BPC collections were completed. The first leukapheresis collection was done on the day when the WBC count exceeded 1.0 ϫ 10 9 /l after the Cy-induced nadir. 6 The remaining 43 patients received G-CSF alone at a dose of 10-12 g/kg/day for 5 or 6 days with leukapheresis beginning on day 5. Cells were collected using either Spectra (Cobe Laboratories, Lakewood, CO, USA) or CS3000 plus (Baxter Fenwal Division, Deerfield, IL, USA) blood cell separators to process 9 l of blood per collection. Cells were frozen in a controlled-rate freezer at −1°C per min and stored in liquid nitrogen. × 4) and carmustine (500 mg/m 2 ) as previously described. 24 Patients with multiple myeloma received busulfan (3 mg/kg × 4), Cy (90 mg/kg), and melphalan (100 mg/m 2 ) as described previously. 25 Patients with non-Hodgkin's lymphoma received etoposide (1.8 g/m 2 ), Cy (50 mg/kg × 3) and total body irradiation (200 cGy twice daily × 3). 26 Of the 71 patients receiving BPC transplants six could not be evaluated for blood cell recovery because they received autologous marrow as well as mobilized peripheral blood (n = 4) or died within a few days of the BPC transplant procedure (n = 2).
Nineteen of the 90 patients who underwent leukapheresis (10 following mobilization with Cy and G-CSF and nine following G-CSF alone) did not receive autologous BPC transplants because of disease progression (n = 7), severe morbidity following high-dose Cy precluding subsequent intensive therapy (n = 2), refusal of further therapy (n = 2), collection of inadequate numbers of BPC (n = 2), collection of BPC for possible use at a time of future disease progression (n = 2), use of a mafosfamide-purged autologous marrow transplant rather than BPC (n = 1), or a decision to proceed to allogeneic marrow rather than BPC transplant (n = 3).
Thus, 65 patients were analyzed for blood cell recovery post-autologous BPC transplant. However, the other 25 patients are included in the analysis of progenitor mobilization (Table 1) .
Patients had daily morning complete blood counts performed. Packed red blood cell transfusions were given when the hemoglobin was less than 90 g/l while platelet transfusions were given if the platelet count was less than 20 ϫ 10 9 /l. The day of the last platelet transfusion required to maintain this platelet count was chosen as the day of 'platelet recovery'. Most platelet transfusions consisted of a standard dose of five platelet concentrates (ABO-matched for the recipient) containing, on average, 3.5 × 10 11 platelets. However, 25% of all platelet transfusions were ABO-matched apheresis platelets containing a mean of 5 ϫ 10 11 platelets. 27 Apheresis platelets were administered to any patient requiring transfusion according to their availability. Complete blood counts were performed each morning on inpatients and transfusions administered accordingly.
Quantitation of CD34
+ cells
CD34
+ cells were quantitated as described using ISH-AGE criteria. 21 
Methylcellulose assays for erythroid, granulopoietic and mixed lineage CFC
Aliquots of cryopreserved cells were thawed and all assayed using the same culture conditions and scoring criteria. 28 This involved plating the cells in fetal calf serum (FCS)-containing methylcellulose medium supplemented with 10% agar-stimulated leukocyte-conditioned media and 3 U/ml erythropoietin (Methocult, StemCell Technologies, Vancouver, BC, Canada), and enumeration of colonies of erythroid, granulocyte-macrophage, and both cell types after 18 days. These conditions have subsequently been shown to detect approximately 50% of the number of CFC obtained in assays using optimized concentrations of defined growth factors. 29 
CFC-Mk assays
Aliquots of cryopreserved cells were thawed and plated in serum-free agarose cultures (Megacult, StemCell) with GM-CSF (Novartis) at 20 ng/ml, IL-3 (Norvartis) at 20 ng/ml, Steel factor (Terry Fox Laboratory, Vancouver, BC, Canada) at 100 ng/ml, and IL-6 (Cangene, Mississauga, ON, Canada) at 20 ng/ml and 18 days later, CD41
+ colonies scored after fixation and staining as described. 19 
LTC assays of CFC precursors
Aliquots of cells from thawed BPC collections were cultured on pre-established irradiated human marrow feeders in medium containing 12.5% horse serum, 12.5% FCS, 10 −4 m 2-mercaptoethanol (Myelocult, StemCell) and 10 −6 m freshly dissolved hydrocortisone as previously described. 30 After 10, 35 or 56 days nonadherent and adherent cells were harvested, pooled, washed and assayed in methylcelBone Marrow Transplantation lulose cultures for CFC as described above. We have previously shown that at limiting dilution under these LTC conditions after 35 days, the average number of CFC present per input BPC LTC-initiating cell (LTC-IC) is two. 6 Thus, the number of CFC recovered from 5-week-old LTC can be divided by two to derive LTC-IC numbers from the 'CFC from LTC values' shown in the Results section. However, for LTC analyzed after 10 or 56 days, the CFC output per input BPC LTC-IC has not been determined and may be quite different and even reflect an input LTC-IC with different properties.
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Statistical analysis
All comparisons between different regimens for mobilization of different progenitor classes and count recoveries (Tables 2, 3 , 4, 5) were done using the Mann-Whitney U Wilcoxon rank sum W test for comparisons between two groups and the Kruskal-Wallis one-way Anova test for comparisons of multiple groups. Univariate and multivariate analysis was performed to assess the effects of prior therapy, sex, age, and diagnosis on progenitor mobilization, blood cell recovery and transfusion requirements using Cox's proportional hazards model. 34 The significance of correlation coefficients was established using Student's ttest (Table 6 ). The significance of the threshold values of different cell numbers for predicting blood cell recovery (Table 7) was established using contingency table analysis with the chi-square test. A significance level of P Ͻ 0.05 was chosen.
Results
Comparison of blood cell recoveries and transfusion requirements in recipients of transplants obtained by different mobilization regimens
As shown in Table 2 , the number of collections performed per patient varied significantly among the different mobilization regimens (P Ͻ 0.0001). For the Cy + GM-CSF Ϯ IL-3 regimens, the larger number of leukaphereses performed reflects our policy at that time of performing five or more collections per patient to ensure that у6 ϫ 10 8 nucleated cells per kg had been collected.
Neutrophil and platelet recovery post Cy was significantly more rapid in the group receiving G-CSF as compared to those receiving GM-CSF Ϯ IL-3 ( Table 2 ). There was no significant difference in the number of platelet and red blood cell transfusions administered post mobilization with Cy to any of the patient groups. The median day to neutrophil recovery post transplant was not significantly different for any mobilization strategy used. The median period until the last platelet transfusion was, however, slightly shorter for patients receiving BPC mobilized with Cy + G-CSF as compared to patients receiving cells mobilized with Cy + GM-CSF alone or G-CSF without chemotherapy. This difference, however, did not result in a significant change in the number of platelet (or red blood cell) transfusions required. The use of IL-3 in combination with GM-CSF as an additional mobilizing agent did not improve c P values as shown are for differences among multiple groups determinned using the Kruskal-Wallis one-way Anova test. ANC Ͼ 0.5 = absolute neutrophil count Ͼ0.5 × 10 9 /l; last plt = day of the last platelet transfusion. Table 2 .
The groups who received extensive chemotherapy or radiotherapy as described in the Methods included nine of 10 patients who had BPC mobilization with Cy + GM + IL-3 and all seven patients who received Cy + GM while only seven patients receiving Cy + G and 21 receiving G-CSF alone met these criteria.
the ability of the BPC obtained to significantly accelerate platelet recovery as compared to regimens that used only GM-CSF or G-CSF following Cy.
The effect of prior therapy on blood cell recovery
Sixteen of the 17 (94%) patients who received Cy + GM-CSF Ϯ IL-3 for BPC mobilization had received significant prior therapy with alkylating agents and/or radiotherapy as described in Methods prior to BPC mobilization. In contrast, only 28 of the 73 patients (38%) whose BPC were mobilized with Cy + G-CSF or G-CSF alone had received similar extensive prior therapy. When recoveries following the four different mobilization regimens were analyzed for the 44 patients with extensive prior therapy the only significant (P = 0.04) difference observed was a slightly (2-4 day) faster neutrophil recovery post mobilization for the Cy + G-CSF patients as compared to those who received Cy + GM-CSF Ϯ IL-3. No difference in neutrophil recovery after transplant or platelet recovery after mobilization or transplant was observed among the groups receiving different mobilization regimens. Thus, most of the differences between these four mobilization strategies shown in Table  2 appeared to be accounted for by the variation in the proportion of heavily pretreated patients in different mobilization groups.
To further investigate the effect of previous treatment on recovery and transfusion support post mobilization of BPC and post transplant the entire group of 90 patients was analyzed according to the amount of prior chemotherapy and/or radiotherapy received. Table 3 demonstrates that after mobilization, recovery was significantly more rapid 593 Table 4 Cells collected per 9 l leukapheresis after different mobilization regimens b P values shown are for differences among all the groups determined as for Table 2 . When the individual groups were compared to one another using the Wilcoxon rank sum test significant (P Ͻ 0.05) differences were seen for CFC-Mk when the Cy + G group was compared to those receiving G alone or Cy + GM + IL-3 and when the Cy + GM + IL-3 group was compared to Cy + GM. For total CFC the only significant difference between the groups was between Cy + G and G alone (P Ͻ 0.002). For CD34 + cells there was a significant difference between G alone and Cy + G or Cy + GM (P Ͻ 0.02). GM ϭ GM-CSF; G = G-CSF. Table 2 . ND = none detected. and the amount of transfusion support administered was less in the group of patients who had received previous therapy that was not intensive as compared to the two other groups. After transplant there was no significant difference in recovery between the three groups of patients. However, more red cell and platelet transfusions were required in the 12 patients who had received extensive prior radiotherapy as compared to the 33 who had received less intense previous therapy (P = 0.02) ( Table 3) . In univariate analyses considering patient age, diagnosis, sex, and whether or not total body irradiation was part of the conditioning regimen, female sex was associated with slower platelet recovery post mobilization with Cy (male vs female, medians 15 vs 18 days, P = 0.05) and a need for more platelet transfusions at this time (P = 0.01). None of the other factors had a significant influence on recovery or transfusion requirements after mobilization or transplant.
In multivariate analysis heavy prior therapy retained its significance for predicting slower neutrophil recovery post Cy (P = 0.03) and the need for more red cell transfusions at that time (P = 0.02) while slower platelet recovery post Cy and the need for larger numbers of platelets post Cy in the heavily pre-treated group retained near significance (P = 0.075 and P = 0.06, respectively). In the same analysis female sex continued to predict delayed platelet recovery post Cy (P = 0.08) and the need for more platelet transfusions (P = 0.02). The need for more platelet transfusions after transplant in patients who had previously received radiotherapy also retained significance (P = 0.05).
Analyses of BPC harvests
Marked variability in the number of CD34 + cells and progenitors of all types collected was seen regardless of the regimen used for mobilization (Table 4) . However, when the numbers of cells collected were compared according to the regimen used, significantly more CFC-Mk, total CFC, and CD34
+ cells were obtained per leukapheresis using Cy + G-CSF than G-CSF alone. The coadministration of IL-3 and GM-CSF following Cy did not improve the mobilization of any cell type over that which could be achieved with Cy + GM-CSF alone. In fact, the number of CFC-Mk mobilized were greater (P Ͻ 0.05) with Cy + G-CSF or Cy + GM-CSF as compared to Cy + GM-CSF + IL-3.
There were no significant differences in numbers of CFC from 5 week LTC (LTC-IC) harvested following the different mobilizing regimens. CFC generated after a shorter (10 day) or longer (8 week) period in LTC were also assessed with similar results except that the values were higher (median 6 ϫ 10 6 , range Ͻ0.1-120 ϫ 10 6 per leukapheresis) for the 10 day assays and lower for the 8 week assays (range Ͻ0.1-830 ϫ 10 3 per leukapheresis with no CFC detected in 8-week-old LTC from 52 of 78 collections tested), respectively.
The effect of prior chemotherapy and/or radiation the patients had received on the number of progenitors mobilized, is shown in Table 5 . The number of each cell type measured was significantly lower in collections from heavily pretreated patients. Multivariate analysis confirmed this association for total CFC (P = 0.03). However, no significant difference was seen in the numbers of any mobilized cell type between patients compromised by chemotherapy and those who had received radiotherapy.
Both univariate and multivariate analyses revealed a significant association of female sex with a reduced yield of CD34 + cells (P = 0.02 and 0.008, respectively) but neither age nor diagnosis were significant factors.
Comparison of doses of different progenitor types in individual leukapheresis products
The number of CD34 + cells and total CFC in different patients' harvests were strongly correlated (r = 0.75, P Ͻ 0.001) ( Table 6 ) and a similarly strong correlation was observed between total CFC and either CFC-Mk (r = 0.65, P Ͻ 0.001) or day 10 LTC CFC (r = 0.62, P Ͻ 0.001). A weaker, but still significant, correlation was found between the number of CD34
+ cells and CFC-Mk, day 10 LTC CFC, and week 5 LTC CFC. Week 5 LTC CFC numbers showed a strong correlation with week 8 LTC CFC numbers (r = 0.62, P Ͻ 0.001) and a somewhat weaker relationship with day 10 LTC CFC (r = 0.50, P Ͻ 0.001) ( Table 6) .
Relationship between recovery after transplant and the number of progenitors transplanted
Sixty-five patients subsequently received myeloablative treatments and transplantation of their BPC harvests. In spite of the Ͼ100-fold variation in the numbers of CD34 + cells transplanted (per kg), the time to recovery of neutrophils to Ͼ0.5 ϫ 10 9 /l was highly predictable at between 8 and 17 (median of 13) days post transplant. Two unusual patients showed very delayed and unexplained neutrophil recoveries at 32 and 33 days post transplant.
All 65 patients required at least one platelet transfusion and only one became transfusion-independent before day 6. Fourteen (22%) had their platelet recoveries delayed beyond day 21 and 4 (6%) beyond day 60. As is evident in Figure 1a , delayed platelet recoveries were seen primarily in patients that received relatively low numbers of CD34 + cells (or low numbers of total CFC, data not shown). Delayed platelet recoveries were also confined to patients Bone Marrow Transplantation who received relatively low numbers of CFC-Mk ( Figure  1b) ; however, rapid platelet recovery could occur regardless of the number of CFC-Mk infused. No obvious relationship between platelet recovery and the CFC precursor content of the graft as assessed in day 10, week 5 or week 8 LTC assays was apparent (data not shown).
From the number of different progenitor cell types infused and platelet count recoveries post transplant for each patient, threshold progenitor doses associated with a rapid platelet recovery were determined. As shown in Table  7 , more than 90% of patients required no platelet transfusions after day 28 when they received a transplant containing more than 2 ϫ 10 6 CD34 + cells, 5 ϫ 10 5 total CFC, 2.5 ϫ 10 4 CFC-Mk, or 1000 CFC detected in 5 week LTC (per kg). The differences in days to platelet recovery between patients receiving cell doses above and below these thresholds was highly significant (P р 0.0002) for CD34
+ cells, CFC-Mk and total CFC but not for LTC CFC (P = 0.24). Thus, assessment of CD34 + cell numbers was as reliable as any other individual measurement tested in predicting platelet recovery post BPC transplant. In fact, only two patients had platelet recovery delayed beyond day 28 (to days 57 and 63, respectively) when Ͼ2 ϫ 10 6 CD34
+ cells/kg were infused. Interestingly however, in both of these cases the dose of CD34 + cells was 'borderline' at 2.4 ϫ 10 6 /kg. Six of 18 patients transplanted with р2 ϫ 10 6 CD34
+ cells/kg were platelet transfusion-independent by day 14 ( Table 7) . We next examined the possibility that combining CFC measurements with CD34 + cell enumeration might allow such people to be identified as being at low risk for delayed platelet recovery. In fact, five of these six patients were among the seven who had received transplants containing low numbers of CD34 + cells but Ͼ2.5 ϫ 10 4 CFCMk and/or Ͼ5 ϫ 10 5 total CFC per kg. The other two patients in this latter group exhibited delayed platelet recoveries at days 41 and 63. In contrast, six of 11 patients who received р2 ϫ 10 6 CD34 + cells, as well as р2.5 ϫ 10 4 CFC-Mk and р5 ϫ 10 5 CFC per kg still required platelet transfusions after day 28, and in three cases beyond day 60.
Discussion
Since the widespread adoption of CD34
+ cell enumeration and G-CSF and GM-CSF for BPC mobilization, neutrophil recovery has become quite reliable post-BPC transplant. 1, 7, 8, 14, 35 However, a significant proportion of patients still show delayed recoveries of their platelets, in some cases for many months. 6, 8, 18 Thus, interest continues in the identification of additional measurements that might help identify such patients proactively. In this study, we assessed several such endpoints simultaneously with standard CFC and CD34
+ cell measurements in a series of BPC collections harvested at a single centre over a 6-year period from 90 patients, 65 of whom subsequently proceeded to transplantation. The new endpoints included a sensitive and specific method for quantifying megakaryocyte lineage-restricted precursors (CFC-Mk) 19 as well as more primitive precursors that generate CFC found in LTC (containing pre-established feeders) after 10, 35 and 56 days. Other investigators have measured cells of the Mk lineage in BPC collections using either flow cytometry or colony assays. 11, 36 In one case, 36 a positive relationship with platelet recovery was shown and a predictive advantage over the standard measurement of CD34 + cell numbers was suggested. Our findings with CFC-Mk measurements are consistent with these results. However, we were unable to demonstrate that quantitation of these progenitors offers an advantage over measurements of total CFU-GM and BFU-E or CD34 + cell numbers. Nevertheless, we did find that most patients transplanted with Ͻ2 ϫ 10 6 CD34 + cells/kg who had platelet recovery within 28 days had received doses of clonogenic cells that were above the thresholds that predict rapid platelet recovery for 90% of our patients. Thus, although routine measurement of CFC numbers does not appear to be necessary when more than 2 ϫ 10 6 CD34 + cells/kg are collected, when fewer CD34 + cells are available, CFC enumeration may allow for more accurate prediction of count recovery than is obtained by CD34
+ cell numbers alone.
In a previous smaller study we were unable to demonstrate a relationship between the number of CFC detected after 5 weeks in LTC transplanted and count recovery. 6 The present much larger series confirms and extends these observations to a broader range of primitive progenitor activities detected using CFC outputs after various periods of time in LTC. The 10 day point corresponds most closely with the ⌬CFC endpoint reported on extensively by Moore and coworkers 37 and probably identifies progenitors with proliferative and self-renewal capabilities intermediate between the majority of directly clonogenic progenitors and LTC-IC measured using a 5 week CFC endpoint. 20 There is also some evidence that more prolonged CFC outputs may identify even more primitive cells. 33, 38 However, none of these measurements enabled transplants to be identified that were likely to put patients at risk for prolonged posttransplant thrombocytopenia. Thus, LTC measurements appear to be less useful than standard CFC or CD34 + cell enumeration for predicting short-term recovery after transplant. It remains possible that the number of progenitors detected in LTC assays might be more useful for predicting long-term hematopoietic graft function because some of these cells appear to be closely related to long-term in vivo repopulating cells. 39 However, none of the patients in our series experienced late graft failure, precluding further examination of this issue in the present study.
The effect of four different regimens (G-CSF, Cy + GM-CSF ± IL-3 and Cy + G-CSF) on BPC mobilization and count recovery after transplant were also compared. Overall, we found no important advantage in progenitor mobilization, platelet recovery, or platelet transfusion requirement to the use of any one of these regimens. In addition, administration of IL-3 in our patient population was associated with significant side-effects, including fever, headache and weight gain. Other investigators have suggested that the use of IL-3 may speed platelet recovery following nonmyeloablative chemotherapy 40 and that the sequential use of IL-3 and GM-CSF following chemotherapy may enhance progenitor mobilization. 10 The discrepancy between these results and our own probably reflect both the different drug schedules and dosages employed and differences in the patient populations studied. In particular, all but one of the patients receiving GM-CSF Ϯ IL-3 in this study had received extensive prior chemotherapy and/or radiotherapy. It is quite possible that enhanced progenitor mobilization and count recoveries would have been demonstrated with the addition of IL-3 in a less heavily pretreated group. This, in fact, appears to have been the case in previous studies. 10 The importance of pre-existing clinical characteristics to the success of BPC mobilization is further illustrated by our analysis of the effect of prior chemo/radiotherapy. As shown in Table 5 , BPC mobilization is generally more difficult in patients who have received extensive chemo/radiotherapy. Others have also found previous chemotherapy to be highly predictive of reduced BPC mobilization. 16, 18, 23 However, of the 32 heavily pre-treated patients in this group who proceeded to autologous transplantation 26 recovered their platelets by day 28 and in 19 platelet recovery had occurred by day 14. On the other hand, among the 46 patients who had had very little prior therapy, Ͻ2 ϫ 10 6 CD34 + cells/kg were mobilized in 10 cases and in the 33 who were subsequently transplanted four failed to recover their platelets by day 28. Thus, although extensive prior therapy predicts reduced BPC mobilization this does not usually preclude collection of sufficient BPC to ensure rapid hematologic reconstitution after autologous transplantation. On the other hand, the absence of extensive prior therapy does not guarantee that adequate BPC harvests will be obtained using any of the mobilization regimens evaluated here. There must be additional important variables affecting either the size of the marrow progenitor pool, its ability to be mobilized and/or its sensitivity to 'myeloablative' therapy and subsequent ability to contribute endogenously to hematologic recovery. 41, 42 The ability of the marrow microenvironment to stimulate hematologic recovery after myeloablation may also be a significant factor. Each of these parameters is likely to be influenced by mechanisms which could be complex and difficult to resolve. Thus, for some time, reliance on empirical data from large clinical studies may be required to evaluate new mobilizing regimens and the utility of the BPC they can yield. In this regard, it is interesting to note that, in the present study, mobilized CFC-Mk and granulopoietic plus erythroid (total) CFC numbers were strongly correlated suggesting that all of these progenitors are released from the marrow by common mechanisms. This finding is consistent with results of others 11, 43 as well as our own observation that LTC-IC are mobilized into the peripheral blood with similar kinetics to those of CFC. 
